The good news is that the vaccine can be stored at a normal refrigeration temperature with no need to be frozen at extremely low temperatures. The other good news is that the J&J vaccine requires only one dose instead of two doses as required by the Pfizer (PFE) and Moderna (MRNA) vaccines.
While access to the J&J vaccine might be limited at first, the firm affirmed that it can bring in millions of doses in the second half of 2021.
As we wrote before, the world needs a lot of vaccines to declare a total victory against SARS-CoV2 (the virus that causes COVID-19) and its novel strains. We are waiting to have more approved vaccines from other firms which include, CureVac (CVAC), Novavax (NVAX) and Inovio (INO) as well as many other biotech and biopharma firms.
We will soon declare victory against COVID-19.
To read more about COVID-19 please click here.
Johnson & Johnson COVID-19 Vaccine Voting Tomorrow with Expected Approval on Saturday
Johnson & Johnson COVID-19 Vaccine
According to a new analysis posted online by the FDA, the Johnson & Johnson (JNJ) vaccine is providing strong protection against severe disease and death related to COVID-19 infection. The vaccine may reduce the spread of the virus from vaccinated people. The vaccine is said to have a 72% efficacy rate in the U.S. and 64% in South Africa.
The vaccine has demonstrated 86% efficacy against severe forms of COVID-19. The FDA could authorize selling the vaccine as early as this Saturday, depending on the voting by the FDA vaccine advisory panel tomorrow, Friday, February 26, 2021.